Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Adagio Medical Holdings ( (ADGM) ) has shared an update.
On September 5, 2025, Adagio Medical Holdings appointed Deborah Kaster as Chief Financial Officer, expanding her role from Chief Business Officer. Kaster, who joined Adagio in March 2025, brings over 25 years of financial leadership experience and will oversee both business and financial operations. This strategic move aims to align Adagio’s financial and strategic priorities, enhancing its growth potential in the medical device industry.
The most recent analyst rating on (ADGM) stock is a Hold with a $1.50 price target. To see the full list of analyst forecasts on Adagio Medical Holdings stock, see the ADGM Stock Forecast page.
Spark’s Take on ADGM Stock
According to Spark, TipRanks’ AI Analyst, ADGM is a Neutral.
Adagio Medical Holdings faces significant financial challenges, with consistent losses and negative cash flows weighing heavily on its overall score. While technical indicators show some short-term bullish trends, the negative P/E ratio and lack of dividend yield are concerning from a valuation perspective. However, recent corporate events indicate positive strategic developments, which could improve future prospects.
To see Spark’s full report on ADGM stock, click here.
More about Adagio Medical Holdings
Adagio Medical Holdings, Inc. is a medical device company specializing in the development and commercialization of products for treating cardiac arrhythmias using its proprietary Ultra-Low Temperature Cryoablation (ULTC) technology. The company focuses on ventricular tachycardia treatment with its vCLAS™ Cryoablation System, which is CE Marked and under evaluation in the U.S. FULCRUM-VT IDE Pivotal Study.
Average Trading Volume: 40,570
Technical Sentiment Signal: Hold
Current Market Cap: $24.3M
Learn more about ADGM stock on TipRanks’ Stock Analysis page.